Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Grace Xie
IRKintor Pharmaceuticals
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Mr. Mark Chen
BD DirectorKlUnited States Pharma
Biologics Therapeutic development focUnited Statesed on oncology and IO. Looking for potential partnership opportunities for license in/out. www. KlUnited Statespharma.com
Laura Hong
Presidentleadermed Group
leadermed Group是一家将美国正在临床阶段创新药license in China以及亚洲部分国家的公司,致力于将国外最新研究成果以最快速度让China乃至亚洲其他国家患者使用上国际最安全有效创新药,将来也将自主研发我们China人自己的创新药,为世界上所有患者服务!
Hongjian红健 Shen沈
共同创始合伙人lh@foncoo.com
Foncoo was founded in 1999, headquartered in Shenzhen, is a specialty pharmaceutical company with more than 20 years of experience focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases in China.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine.
Lee Vanco
BD managerLink Health Group
Link Health is a leading Chinese pharmaceutical company based in Southern China, focusing on the development of innovative drugs for the unmet medical needs.
Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, favourable regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently.
The company has established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office focuses on collaborations with global pharma/biotech partners and research institutes.
Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, favourable regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently.
The company has established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office focuses on collaborations with global pharma/biotech partners and research institutes.